News >

Chemotherapy Remains Critical in NSCLC Paradigm

Caroline Seymour
Published: Thursday, Apr 26, 2018

Mark G. Kris, MD

Mark G. Kris, MD
Although targeted therapy and immunotherapy have been well validated, chemotherapy has been and will remain integral to the treatment of patients with non–small cell lung cancer (NSCLC), says Mark G. Kris, MD.

State of the Science Summit™ on Advanced Non–Small Cell Lung Cancer, Kris, William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center, discussed the continued significance of chemotherapy in patients with NSCLC in the era of targeted agents and immunotherapy.

OncLive: Please provide an overview of your presentation.

Kris: My topic of discussion tonight is the use of chemotherapy. By chemotherapy, I mean drugs that target the cell cycle. There is a misconception that chemotherapy is not a targeted treatment, but it actually is. We're not quite as sure about the target as we are perhaps with EGFR tyrosine kinase inhibitors (TKIs), but we know how it works. Chemotherapy does affect cells, particularly cells that have already undergone a neoplastic transformation. Chemotherapy given with radiation, or given before or after surgery can improve the chance of cure. It's really the only treatment today that can do that.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication